Global, Regional, and National cancer incidence, mortality, Years of Life Lost, Years lived with Disability, and Disability-Adjusted Life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of disease study.

JAMA Oncol. 4: 1553-1568Christiansen C.F. Johansen M.B. Langeberg W.J. Fryzek J.P. Sørensen H.T.

Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study.

Eur J Intern Med. 22: 399-406Khalil M.A.M. Latif H. Rehman A. et al.

Acute kidney injury in lymphoma: a single centre experience.

Int J Nephrol. 2014: 272961Munker R. Hill U. Jehn U. Kolb H.J. Schalhorn A.

Renal complications in acute leukemias.

Haematologica. 83: 416-421Canet E. Zafrani L. Lambert J. et al.

Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival.

PLoS One. 8: e55870Luciano R.L. Brewster U.C.

Kidney involvement in leukemia and lymphoma.

Adv Chronic Kidney Dis. 21: 27-35Filippatos T.D. Milionis H.J. Elisaf M.S.

Alterations in electrolyte equilibrium in patients with acute leukemia.

Eur J Haematol. 75: 449-460Santoriello D. Andal L.M. Cox R. D’Agati V.D. Markowitz G.S.

Lysozyme-induced nephropathy.

Kidney Int Rep Elsevier Inc. 2: 84-88Liamis G. Liberopoulos E. Barkas F. Elisaf M.

Spurious electrolyte disorders: a diagnostic challenge for clinicians.

Am J Nephrol. 38: 50-57Asirvatham J.R. Moses V. Bjornson L.

Errors in potassium measurement: a laboratory perspective for the clinician.

North Am J Med Sci. 5: 255-259Uprety D. Peterson A. Shah B.K.

Renal failure secondary to leukemic infiltration of kidneys in CLL--a case report and review of literature.

Ann Hematol. 92: 271-273

Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82.

Matsuhashi Y. Tasaka T. Euhara E. et al.

Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis. Leukemia and Lymphoma.

Leuk Lymphoma. 45: 397-400Puri I. Sharma D. Gunturu K.S. Ahmed A.A.

Diagnosis and management of tumor lysis syndrome.

J Community Hosp Intern Med Perspect. 10: 269-272Ikeda K. Ohno H. Hane M. et al.

Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: Evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma.

J Clin Endocrinol Metab. 79: 1322-1327Vallet N. Ertault M. Delaye J.B. et al.

Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases.

Ann Hematol. 99: 229-239Rosner M.H. Jhaveri K.D. McMahon B.A. Perazella M.A.

Onconephrology: the intersections between the kidney and cancer.

CA: A Cancer J Clinicians. 71: 47-77

79 - tumor Genesis syndrome: severe Hypophosphatemia associated with progression of diffuse large B-cell lymphoma.

Can J Diabetes. 43: S29-S30Ruiz J.P. Singh A.K. Hart P.

Type B lactic acidosis secondary to malignancy: case report, review of published cases, insights into pathogenesis, and prospects for therapy.

ScientificWorldJournal. 11: 1316-1324Giammarco S. Chiusolo P. Piccirillo N. et al.

Hyperleukocytosis and leukostasis: management of a medical emergency.

Expert Rev Hematol. 10: 147-154Ganguli A. Sawinski D. Berns J.S.

Kidney diseases associated with haematological cancers.

Nat Rev Nephrol. 11: 478-490Levin M.D. Betjes M.G. VdK T.H. Wenberg B.L. Leebeek F.W.

Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia.

Haematologica. 88: Ecr21Thiébaut A. Thomas X. Belhabri A. Anglaret B. Archimbaud E.

Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis.

Ann Hematol. 79: 501-506

Coagulation factors in nephrotic syndrome.

Am J Nephrol. 10: 63-68Weaver A. Rubinstein S. Cornell R.F.

Hyperviscosity syndrome in paraprotein Secreting conditions including Waldenstrom macroglobulinemia.

Front Oncol. 10: 815

Evidence-based focused review of management of hyperviscosity syndrome.

Blood. 119: 2205-2208Ramos-Casals M. Stone J.H. Cid M.C. Bosch X.

The cryoglobulinemia.

Lancet. 379: 348-360

Cryoglobulinemia.

Hematol Am Soc Hematol Educ Program. 2005: 368-372Saadoun D. Sellam J. Ghillani-Dalbin P. Crecel R. Piette J.-C. Cacoub P.

Increased risks of lymphoma and death among patients with non–hepatitis C virus–related mixed cryoglobulinemia.

Arch Intern Med. 166: 2101-2108Muchtar E. Magen H. Gertz M.A.

How I treat cryoglobulinemia.

Blood. 129: 289-298Palma L.M.P. Sridharan M. Sethi S.

Complement in secondary thrombotic microangiopathy.

Kidney Int Rep. 6: 11-23Ravindran A. Go R.S. Fervenza F.C. Sethi S.

Thrombotic microangiopathy associated with monoclonal gammopathy.

Kidney Int. 91: 691-698Kratochvil D. Amann K. Bruck H. Büttner M.

Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia.

BMC Nephrol. 13: 172Vos J.M. Gustine J. Rennke H.G. et al.

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.

Br J Haematol. 175: 623-630Audard V. Georges B. Vanhille P. et al.

Renal lesions associated with IgM-Secreting monoclonal Proliferations: Revisiting the disease spectrum.

Clin J Am Soc Nephrol. 3: 1339Strati P. Nasr S.H. Leung N. et al.

Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.

Haematologica. 100: 1180-1188Izzedine H. Perazella M.A.

Thrombotic microangiopathy, cancer, and cancer drugs.

Am J Kidney Dis. 66: 857-868Usui J. Glezerman I.G. Salvatore S.P. Chandran C.B. Flombaum C.D. Seshan S.V.

Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.

Hum Pathol. 45: 1918-1927Bollée G. Patey N. Cazajous G. et al.

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.

Nephrol Dial Transplant. 24: 682-685Costero O. Picazo M.L. Zamora P. Romero S. Martinez-Ara J. Selgas R.

Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.

Nephrol Dial Transpl. 25: 1001-1003Hanna R.M. Selamet U. Hasnain H. et al.

Development of focal segmental glomerulosclerosis and thrombotic microangiopathy in a liver transplant patient on sorafenib for Hepatocellular carcinoma: a case report.

Transpl Proc. 50: 4033-4037Syed U. Wahlberg K.J. Douce D.R. Sprague J.R.

Thrombotic thrombocytopenic purpura associated with pazopanib.

Case Rep Hematol. 2018: 4327904Kalla S. Ellis R.J. Campbell S.B. et al.

Thrombotic microangiopathy associated with pazopanib in a kidney transplant Recipient.

J Kidney Cancer VHL. 8: 25-31Hyogo Y. Kiyota N. Otsuki N. et al.

Thrombotic microangiopathy with severe proteinuria induced by lenvatinib for Radioactive Iodine-refractory Papillary Thyroid carcinoma.

Case Rep Oncol. 11: 735-741Al Aly Z. Philoctête Ashley J.M. Gellens M.E. González E.A.

Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?.

Am J Kidney Dis. 45: 762-768Ojeda-Uribe M. Merieau S. Guillon M. et al.

Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.

J Oncol Pharm Pract. 22: 361-370Martino S. Daguindau E. Ferrand C. et al.

A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.

Leuk Res Rep. 2: 29-31Demirsoy E.T. Mehtap O. Atesoglu E.B. et al.

Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura.

Transfus Apher Sci. 57: 222-224Jindal N. Jandial A. Jain A. et al.

Carfilzomib-induced thrombotic microangiopathy: a case based review.

Hematol Oncol Stem Cell Ther. S1658-3876: 30118-7https://doi.org/10.1016/j.hemonc.2020.07.001Magee C.C. Abraham K. Farrell J. Dorman T. Walshe J.J.

Renal thrombotic microangiopathy associated with interferon-α treatment of chronic myeloid leukemia.

Am J Kidney Dis. 36: e5.1-e5.5Sureka S.K. Yadav P. Kumar P. Srivastava A.

Renal vein thrombosis as presentation of non-M3 acute myeloid leukemia in an adult patient.

Indian J Nephrol. 28: 153-156

Hypertension and constriction of the renal arteries in man: report of a case.

Ann Intern Med. 12: 1690-1699

Pathoanatomical features of the kidney in myelomonocytic and chronic lymphocytic leukemia.

Virchows Arch A Pathol Anat Histol. 368: 243-251Barcos M. Lane W. Gomez G.A. et al.

An autopsy study of 1206 acute and chronic leukemias (1958 to 1982).

Cancer. 60: 827-837Xiao J.C. Walz-Mattmüller R. Ruck P. Horny H.P. Kaiserling E.

Renal involvement in myeloproliferative and lymphoproliferative disorders. A study of autopsy cases.

Gen Diagn Pathol. 142: 147-153Sethi A. Rhodes J. Mato A. Hogan J.J.

Chronic lymphocytic leukemia and the kidney.

J Onco-Nephrology. 1: 103-109Gilboa N. Lum G.M. Urizar R.E.

Early renal involvement in acute lymphoblastic leukemia and Nonhodgkin’s lymphoma in children.

J Urol. 129: 364-367Truong L.D. Soroka S. Sheth A.V. Kessler M. Mattioli C. Suki W.

Primary renal lymphoma presenting as acute renal failure.

Am J Kidney Dis. 9: 502-506Törnroth T. Heiro M. Marcussen N. Franssila K.

Lymphomas diagnosed by percutaneous kidney biopsy.

Am J Kidney Dis. 42: 960-971Aratani S. Aburakawa S. Ryotokuji T. et al.

Primary tumor infiltration and severe acute kidney injury in patients with acute Myeloblastic leukemia.

J Nippon Med Sch. 87: 43-48Javaugue V. Debiais-Delpech C. Nouvier M. et al.

Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.

Kidney Int. 96: 94-103Durani U. Shah N.D. Go R.S.

In-hospital outcomes of tumor lysis syndrome: a population-based study using the National Inpatient sample.

Oncologist. 22: 1506-1509

Tumour lysis syndrome: new therapeutic strategies and classification.

Br J Haematol. 127: 3-11Ji J. Mould D.R. Blum K.A. et al.

A Pharmacokinetic/Pharmacodynamic Model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.

Clin Cancer Res. 19: 1269-1280Flynn J. Jones J. Johnson A.J. et al.

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.

Leukemia. 29: 1524-1529Howard S.C. Trifilio S. Gregory T.K. Baxter N. McBride A.

Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.

Ann Hematol. 95: 563-573Yang B. Lu X.C. Yu R.L. et al.

Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma.

Am J Med Sci. 343: 337-341Opyrchal M. Figanbaum T. Ghosh A. Rajkumar V. Caples S.

Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma.

Case Rep Med. 2010: 610969

Spontaneous tumor lysis syndrome: a case report and Critical evaluation of Current diagnostic criteria and optimal treatment Regimens.

J Investig Med High Impact Case Rep. 3Tbakhi B. Hanna S. Samhouri Y. Lingutla D.

Spontaneous tumour lysis syndrome in multiple myeloma with loss of 17p13.1, t(4;14) and monosomy 13.

BMJ Case Rep. 14: e234122Infante J. Casado A. Almeida A. Messias A.

Spontaneous tumor lysis syndrome: a rare presentation in Plasmablastic lymphoma.

J Hematol. 10: 30-34Sherwood G.B. Paschal R.D. Adamski J.

Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm.

Clin Case Rep. 4: 315-319Trachsler J. Gaspert A. Previsdomini M. Wüthrich R.P. Fehr T.

Massive uric acid nephrolithiasis with progressive renal failure due to spontaneous tumour lysis syndrome.

NDT Plus. 1: 307-309

Onco-nephrology: tumor lysis syndrome.

Clin J Am Soc Nephrol. 7: 1730Mirrakhimov A.E. Voore P. Khan M. Ali A.M.

Tumor lysis syndrome: a clinical review.

World J Crit Care Med. 4: 130-138Belliere J. Colombat M. Kounde C. et al.

Kidney involvement in patients with chronic myelomonocytic leukemia or BCR-ABL–negative myeloproliferative neoplasms.

Kidney Int Rep. 6: 737-745Bridoux F. Cockwell P. Glezerman I. et al.

Kidney injury and disease in patients with haematological malignancies.

Nat Rev Nephrol. 17: 386-401https://doi.org/10.1038/s41581-021-00405-7Del Sordo R. Brugnano R. Covarelli C. et al.

Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Clin Nephrol Case Stud. 5: 70-77Alexander M.P. Nasr S.H. Kurtin P.J. et al.

Renal extramedullary hematopoiesis: interstitial and glomerular pathology.

Mod Pathol. 28 : 1574-1583Said S.M. Leung N. Sethi S. et al.

Myeloproliferative neoplasms cause glomerulopathy.

Kidney Int. 80: 753-759Higgins L. Nasr S.H. Said S.M. et al.

Kidney involvement of patients with Waldenstrom macroglobulinemia and other IgM-Producing B cell lymphoproliferative disorders.

Clin J Am Soc Nephrol. 13: 1037-1046

Acute kidney injury in a patient with lymphoma.

J Onco-Nephrology. 4: 66-67Nasr S.H. Shanafelt T.D. Hanson C.A. et al.

Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma.

Ann Diagn Pathol. 19: 130-136Inoue T. Sato T. Okada H. et al.

Granulomatous interstitial nephritis in chronic lymphocytic leukaemia.

Nephrol Dial Transplant. 25: 4107-4109Suzuki Y. Katayama K. Ishikawa E. et al.

Granulomatous interstitial nephritis due to chronic lymphocytic leukemia: a case report.

BMC Nephrol. 18: 348Santoriello D. Andal L.M. Cox R. D’Agati V.D. Markowitz G.S.

Lysozyme-induced nephropathy.

Kidney Int Rep. 2: 84-88Aguado M.J. García de Bustos J. Ojeda E. Quevedo E. Foncillas M.A. Hernandez Navarro F.

Proteinuria caused by lysozymuria mimics nephrotic syndrome.

Nephron. 86: 183Perazella M.A. Eisen R.N. Frederick W.G. Brown E.

Renal failure and severe Hypokalemia associated with acute myelomonocytic leukemia.

Am J Kidney Dis. 22: 462-467Mok C.C. Tam S.C.F. Kwong Y.L.

Pseudonephrotic syndrome caused by lysozymuria.

Ann Intern Med. 121: 818Robinet-Zimmermann G. Rioux-Leclercq N. Frouget T. Le Naoures C.

[Lysozyme-induced nephropathy: a rare cause of renal failure in chronic myelomonocytic leukemia].

Ann Pathol. 40: 478-482Asano M. Hase H. Naruse Y. et al.

A rare cause of acute kidney injury with chronic myelomonocytic leukemia.

CEN Case Rep. 10: 320-325https://doi.org/10.1007/s13730-020-00567-6Abeloff M.D. Lenhard Jr., R.E.

Clinical management of ureteral obstruction secondary to malignant lymphoma.

Johns Hopkins Med J. 134: 34-42Richmond J. Sherman R.S. Diamond H.D. Craver L.F.

Renal lesions associated with malignant lymphomas.

Am J Med. 32: 184-207Chong B.H. Trew P. Meng L. Pitney W.R.

Anuric renal failure due to encasement of the ureters by lymphoma--ureteric obstruction without dilatation.

Aust N Z J Med. 11: 542-544Lepor H. Walshi Patrick C.

Idiopathic retroperitoneal fibrosis.

J Urol. 122: 1-6Thomas M.H. Chisholm G.D.

Retroperitoneal fibrosis associated with malignant disease.

Br J Cancer. 28: 453-458Alvarez Argote J. Bauer F.A. Posteraro A.F. Dasanu C.A.

Retroperitoneal fibrosis due to B-cell non-Hodgkin lymphoma: Responding to rituximab.

J Oncol Pharm Pract. 22: 179-185Ricard L. Abisror N. Droin N. et al.

Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.

Leuk Lymphoma. 59: 2503-2505Chen L.Y.C. Mattman A. Seidman M.A. Carruthers M.N.

IgG4-related disease: what a hematologist needs to know.

Haematologica. 104: 444-455Khosroshahi A. Stone J.H.

Treatment approaches to IgG4-related systemic disease.

Curr Opin Rheumatol. 23: 67-71Kawano M. Saeki T. Nakashima H.

IgG4-related kidney disease and retroperitoneal fibrosis: an update.

Mod Rheumatol. 29: 231-239Somerville C.A. Chmiel R. Niall J.F. Murphy B.F.

Non-dilated urinary tract obstruction.

Med J Aust. 156: 721-723Santos A. Quiroga B. Macías N. Goicoechea M. García-de Vinuesa S.

Idiopathic fibrosis as the cause of obstructive uropathy.

Nefrologia. 33: 439-440Rascoff J.H. Golden R.A. Spinowitz B.S. Charytan C.

Nondilated obstructive nephropathy.

Arch Intern Med. 143: 696-698Spital A. Valvo J.R. Segal A.J.

Nondilated obstructive uropathy.

Urology. 31: 478-482Campochiaro C. Tomelleri A. Cavalli G. Berti A. Dagna L.

Erdheim-Chester disease.

Eur J Intern Med. 26: 223-229Jean-Michel V. Coustans M. Wehbe B. Metes I. Siohan P.

Erdheim Chester disease: a rare obstructive case of acute renal failure.

La Presse Médicale. 45: 1066-1069Cochran D. Cook G. Rensing A. Frimberger D. Meenakshi-Sundaram B.

A rare case of T-cell lymphoma presenting with bilateral nephrolithiasis and acute renal failure.

Urology. 146: 222-224Mirheydar H.S. Banapour P. Massoudi R. et al.

What is the incidence of kidney stones after chemotherapy in patients with lymphoproliferative or myeloproliferative disorders?.

Int Braz J Urol. 40: 772-780Shimabukuro-Vornhagen A. Gödel P. Subklewe M. et al.

Cytokine release syndrome.

J Immunother Cancer. 6: 56

The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature.

Mediterr J Hematol Infect Dis. 3: e2011059Gupta S. Seethapathy H. Strohbehn I.A. et al.

Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma.

Am J kidney Dis. 76: 63-71Aulagnon F. Lapidus N. Canet E. et al.

Acute kidney injury in adults with hemophagocytic lymphohistiocytosis.

Am J Kidney Dis. 65: 851-859

Hematophagic histiocytosis: a report of 23 new patients and a review of the literature..

Medicine. 67: 369-388Li J. Wang Q. Zheng W. et al.

Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients.

Medicine (Baltimore). 93: 100-105Rotz S.J. Leino D. Szabo S. Mangino J.L. Turpin B.K. Pressey J.G.

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.

Pediatr Blood Cancer. 64e26642Gutgarts V. Jain T. Zheng J. et al.

Acute kidney injury after CAR-T cell therapy: low incidence and rapid Recovery.

Biol Blood Marrow Transplant. 26: 1071-1076Lee M.D. Strohbehn I.A. Seethapathy H.S. et al.

Acute kidney injury after the CAR-T therapy Tisagenlecleucel.

Am J Kidney Dis. 77: 990-992

Cytokine release syndrome with chimeric antigen receptor T cell therapy.

Biol Blood Marrow Transplant. 25: e123-e127Maraj A. MacEneaney O. Doyle B. Quinn J.

Lysozyme-induced nephropathy: a rare manifestation of chronic myelomonocytic leukaemia.

Br J Haematol. 189: 393Levi I. Dinour D. Ben-Bassat I. Raanani P.

Acute myeloid leukemia associated with nephrotic syndrome: case report and literature review.

Leuk Lymphoma. 43: 1133-1136Budak-Alpdoğan T. Lawrence R.A. Bayik M. Akoğlu E.

Nephrotic syndrome associated with alpha interferon therapy in chronic myeloid leukemia.

Clin Nephrol. 48: 59-60Talwar R. Dash S.C. Kucheria K.

A case of chronic myeloid leukemia complicated with minimal change nephrotic syndrome.

Acta Haematol. 109: 101-103Sudholt B.A. Heironimus J.D.

Chronic myelogenous leukemia with nephrotic syndrome.

Arch Intern Med. 143: 168-169